nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—FKBP1A—esophageal cancer	0.844	1	CbGaD
Pimecrolimus—MTOR—neck—esophageal cancer	0.00308	0.123	CbGeAlD
Pimecrolimus—FKBP1A—neck—esophageal cancer	0.00277	0.111	CbGeAlD
Pimecrolimus—Everolimus—FKBP1A—esophageal cancer	0.00264	0.333	CrCbGaD
Pimecrolimus—MTOR—epithelium—esophageal cancer	0.0021	0.084	CbGeAlD
Pimecrolimus—MTOR—smooth muscle tissue—esophageal cancer	0.00202	0.081	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—esophageal cancer	0.00189	0.0756	CbGeAlD
Pimecrolimus—FKBP1A—bronchus—esophageal cancer	0.00186	0.0744	CbGeAlD
Pimecrolimus—FKBP1A—smooth muscle tissue—esophageal cancer	0.00182	0.0728	CbGeAlD
Pimecrolimus—Temsirolimus—FKBP1A—esophageal cancer	0.00178	0.225	CrCbGaD
Pimecrolimus—Superinfection—Capecitabine—esophageal cancer	0.00167	0.0456	CcSEcCtD
Pimecrolimus—FKBP1A—trachea—esophageal cancer	0.00167	0.0668	CbGeAlD
Pimecrolimus—MTOR—digestive system—esophageal cancer	0.00159	0.0639	CbGeAlD
Pimecrolimus—Tacrolimus—FKBP1A—esophageal cancer	0.00157	0.198	CrCbGaD
Pimecrolimus—Sirolimus—FKBP1A—esophageal cancer	0.00157	0.198	CrCbGaD
Pimecrolimus—Tonsillitis—Capecitabine—esophageal cancer	0.0015	0.041	CcSEcCtD
Pimecrolimus—FKBP1A—digestive system—esophageal cancer	0.00143	0.0575	CbGeAlD
Pimecrolimus—MTOR—lung—esophageal cancer	0.00133	0.0534	CbGeAlD
Pimecrolimus—FKBP1A—lung—esophageal cancer	0.0012	0.048	CbGeAlD
Pimecrolimus—Leukaemia—Methotrexate—esophageal cancer	0.00105	0.0286	CcSEcCtD
Pimecrolimus—MTOR—lymph node—esophageal cancer	0.000911	0.0365	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—esophageal cancer	0.000819	0.0328	CbGeAlD
Pimecrolimus—Lymphoma—Methotrexate—esophageal cancer	0.000807	0.0221	CcSEcCtD
Pimecrolimus—Leukoderma—Methotrexate—esophageal cancer	0.000664	0.0181	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.000637	0.0174	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Cisplatin—esophageal cancer	0.000635	0.0173	CcSEcCtD
Pimecrolimus—Infection—Carboplatin—esophageal cancer	0.000621	0.017	CcSEcCtD
Pimecrolimus—Bacterial infection—Methotrexate—esophageal cancer	0.000611	0.0167	CcSEcCtD
Pimecrolimus—Furuncle—Methotrexate—esophageal cancer	0.000575	0.0157	CcSEcCtD
Pimecrolimus—Pain—Carboplatin—esophageal cancer	0.000535	0.0146	CcSEcCtD
Pimecrolimus—Throat sore—Capecitabine—esophageal cancer	0.000526	0.0144	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.000521	0.0142	CcSEcCtD
Pimecrolimus—Wheezing—Cisplatin—esophageal cancer	0.000499	0.0136	CcSEcCtD
Pimecrolimus—Body temperature increased—Carboplatin—esophageal cancer	0.000494	0.0135	CcSEcCtD
Pimecrolimus—Skin exfoliation—Cisplatin—esophageal cancer	0.000491	0.0134	CcSEcCtD
Pimecrolimus—Otitis media—Capecitabine—esophageal cancer	0.000487	0.0133	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000474	0.013	CcSEcCtD
Pimecrolimus—CYP3A4—digestive system—esophageal cancer	0.000469	0.0188	CbGeAlD
Pimecrolimus—Rhinorrhoea—Capecitabine—esophageal cancer	0.000468	0.0128	CcSEcCtD
Pimecrolimus—Folliculitis—Methotrexate—esophageal cancer	0.000449	0.0123	CcSEcCtD
Pimecrolimus—Eye irritation—Capecitabine—esophageal cancer	0.000444	0.0121	CcSEcCtD
Pimecrolimus—Skin discolouration—Capecitabine—esophageal cancer	0.00042	0.0115	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Capecitabine—esophageal cancer	0.000417	0.0114	CcSEcCtD
Pimecrolimus—Herpes simplex—Capecitabine—esophageal cancer	0.000411	0.0112	CcSEcCtD
Pimecrolimus—Nasal congestion—Cisplatin—esophageal cancer	0.00041	0.0112	CcSEcCtD
Pimecrolimus—Influenza like illness—Capecitabine—esophageal cancer	0.000368	0.0101	CcSEcCtD
Pimecrolimus—Skin exfoliation—Capecitabine—esophageal cancer	0.000362	0.00988	CcSEcCtD
Pimecrolimus—Face oedema—Cisplatin—esophageal cancer	0.00036	0.00984	CcSEcCtD
Pimecrolimus—Breast disorder—Cisplatin—esophageal cancer	0.000337	0.00921	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Cisplatin—esophageal cancer	0.000334	0.00911	CcSEcCtD
Pimecrolimus—Ear pain—Capecitabine—esophageal cancer	0.000322	0.00881	CcSEcCtD
Pimecrolimus—Bone disorder—Methotrexate—esophageal cancer	0.000312	0.00853	CcSEcCtD
Pimecrolimus—Skin discolouration—Methotrexate—esophageal cancer	0.000312	0.00853	CcSEcCtD
Pimecrolimus—Swelling—Capecitabine—esophageal cancer	0.000312	0.00852	CcSEcCtD
Pimecrolimus—Gastroenteritis—Capecitabine—esophageal cancer	0.00031	0.00848	CcSEcCtD
Pimecrolimus—Herpes simplex—Methotrexate—esophageal cancer	0.000306	0.00836	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000292	0.00796	CcSEcCtD
Pimecrolimus—Conjunctivitis—Cisplatin—esophageal cancer	0.00028	0.00763	CcSEcCtD
Pimecrolimus—Skin exfoliation—Methotrexate—esophageal cancer	0.000269	0.00736	CcSEcCtD
Pimecrolimus—Face oedema—Capecitabine—esophageal cancer	0.000266	0.00725	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Capecitabine—esophageal cancer	0.000251	0.00686	CcSEcCtD
Pimecrolimus—Breast disorder—Capecitabine—esophageal cancer	0.000249	0.00679	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Capecitabine—esophageal cancer	0.000246	0.00672	CcSEcCtD
Pimecrolimus—Eye disorder—Cisplatin—esophageal cancer	0.000241	0.00659	CcSEcCtD
Pimecrolimus—Flushing—Cisplatin—esophageal cancer	0.00024	0.00654	CcSEcCtD
Pimecrolimus—Asthma—Capecitabine—esophageal cancer	0.000238	0.00649	CcSEcCtD
Pimecrolimus—Influenza—Capecitabine—esophageal cancer	0.000238	0.00649	CcSEcCtD
Pimecrolimus—Immune system disorder—Cisplatin—esophageal cancer	0.000233	0.00637	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Cisplatin—esophageal cancer	0.000233	0.00635	CcSEcCtD
Pimecrolimus—Bronchitis—Capecitabine—esophageal cancer	0.000229	0.00624	CcSEcCtD
Pimecrolimus—Erythema—Cisplatin—esophageal cancer	0.000225	0.00614	CcSEcCtD
Pimecrolimus—Malnutrition—Cisplatin—esophageal cancer	0.000225	0.00614	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000221	0.00603	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000217	0.00593	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000217	0.00593	CcSEcCtD
Pimecrolimus—Pneumonia—Capecitabine—esophageal cancer	0.000213	0.00582	CcSEcCtD
Pimecrolimus—Infestation—Capecitabine—esophageal cancer	0.000212	0.00579	CcSEcCtD
Pimecrolimus—Infestation NOS—Capecitabine—esophageal cancer	0.000212	0.00579	CcSEcCtD
Pimecrolimus—Conjunctivitis—Capecitabine—esophageal cancer	0.000206	0.00563	CcSEcCtD
Pimecrolimus—Epistaxis—Capecitabine—esophageal cancer	0.0002	0.00546	CcSEcCtD
Pimecrolimus—Rhinitis—Capecitabine—esophageal cancer	0.000191	0.00521	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00019	0.00519	CcSEcCtD
Pimecrolimus—Pharyngitis—Capecitabine—esophageal cancer	0.000189	0.00516	CcSEcCtD
Pimecrolimus—Breast disorder—Methotrexate—esophageal cancer	0.000185	0.00505	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Cisplatin—esophageal cancer	0.000183	0.00501	CcSEcCtD
Pimecrolimus—Oedema—Cisplatin—esophageal cancer	0.000183	0.00501	CcSEcCtD
Pimecrolimus—Infection—Cisplatin—esophageal cancer	0.000182	0.00498	CcSEcCtD
Pimecrolimus—Nervous system disorder—Cisplatin—esophageal cancer	0.00018	0.00491	CcSEcCtD
Pimecrolimus—Skin disorder—Cisplatin—esophageal cancer	0.000178	0.00487	CcSEcCtD
Pimecrolimus—Eye disorder—Capecitabine—esophageal cancer	0.000178	0.00486	CcSEcCtD
Pimecrolimus—Asthma—Methotrexate—esophageal cancer	0.000177	0.00483	CcSEcCtD
Pimecrolimus—Flushing—Capecitabine—esophageal cancer	0.000177	0.00482	CcSEcCtD
Pimecrolimus—Immune system disorder—Capecitabine—esophageal cancer	0.000172	0.00469	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Capecitabine—esophageal cancer	0.000172	0.00468	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000167	0.00456	CcSEcCtD
Pimecrolimus—Erythema—Capecitabine—esophageal cancer	0.000166	0.00452	CcSEcCtD
Pimecrolimus—Malnutrition—Capecitabine—esophageal cancer	0.000166	0.00452	CcSEcCtD
Pimecrolimus—Paraesthesia—Cisplatin—esophageal cancer	0.000165	0.0045	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000164	0.00449	CcSEcCtD
Pimecrolimus—Dyspnoea—Cisplatin—esophageal cancer	0.000164	0.00447	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000162	0.00441	CcSEcCtD
Pimecrolimus—Back pain—Capecitabine—esophageal cancer	0.00016	0.00438	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—esophageal cancer	0.000159	0.00434	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000158	0.00432	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—esophageal cancer	0.000158	0.00431	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—esophageal cancer	0.000158	0.00431	CcSEcCtD
Pimecrolimus—Pain—Cisplatin—esophageal cancer	0.000157	0.00428	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—esophageal cancer	0.000153	0.00419	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—esophageal cancer	0.000149	0.00407	CcSEcCtD
Pimecrolimus—Body temperature increased—Cisplatin—esophageal cancer	0.000145	0.00396	CcSEcCtD
Pimecrolimus—Cough—Capecitabine—esophageal cancer	0.000145	0.00395	CcSEcCtD
Pimecrolimus—Arthralgia—Capecitabine—esophageal cancer	0.000141	0.00385	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—esophageal cancer	0.000141	0.00384	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00014	0.00383	CcSEcCtD
Pimecrolimus—Oedema—Capecitabine—esophageal cancer	0.000135	0.00369	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cisplatin—esophageal cancer	0.000135	0.00369	CcSEcCtD
Pimecrolimus—Infection—Capecitabine—esophageal cancer	0.000134	0.00367	CcSEcCtD
Pimecrolimus—Nervous system disorder—Capecitabine—esophageal cancer	0.000133	0.00362	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—esophageal cancer	0.000132	0.00362	CcSEcCtD
Pimecrolimus—Skin disorder—Capecitabine—esophageal cancer	0.000131	0.00359	CcSEcCtD
Pimecrolimus—Temsirolimus—ABCB1—esophageal cancer	0.000131	0.0166	CrCbGaD
Pimecrolimus—Immune system disorder—Methotrexate—esophageal cancer	0.000128	0.00349	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—esophageal cancer	0.000128	0.00349	CcSEcCtD
Pimecrolimus—Diarrhoea—Cisplatin—esophageal cancer	0.000125	0.00343	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—esophageal cancer	0.000123	0.00337	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—esophageal cancer	0.000123	0.00337	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000123	0.00336	CcSEcCtD
Pimecrolimus—Paraesthesia—Capecitabine—esophageal cancer	0.000121	0.00332	CcSEcCtD
Pimecrolimus—Dyspnoea—Capecitabine—esophageal cancer	0.000121	0.00329	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—esophageal cancer	0.000119	0.00326	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000117	0.00319	CcSEcCtD
Pimecrolimus—Vomiting—Cisplatin—esophageal cancer	0.000117	0.00318	CcSEcCtD
Pimecrolimus—Rash—Cisplatin—esophageal cancer	0.000116	0.00316	CcSEcCtD
Pimecrolimus—Pain—Capecitabine—esophageal cancer	0.000116	0.00316	CcSEcCtD
Pimecrolimus—Constipation—Capecitabine—esophageal cancer	0.000116	0.00316	CcSEcCtD
Pimecrolimus—Dermatitis—Cisplatin—esophageal cancer	0.000116	0.00316	CcSEcCtD
Pimecrolimus—Sirolimus—ABCB1—esophageal cancer	0.000116	0.0146	CrCbGaD
Pimecrolimus—Tacrolimus—ABCB1—esophageal cancer	0.000116	0.0146	CrCbGaD
Pimecrolimus—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000111	0.00302	CcSEcCtD
Pimecrolimus—Nausea—Cisplatin—esophageal cancer	0.000109	0.00298	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—esophageal cancer	0.000108	0.00294	CcSEcCtD
Pimecrolimus—Urticaria—Capecitabine—esophageal cancer	0.000107	0.00293	CcSEcCtD
Pimecrolimus—Abdominal pain—Capecitabine—esophageal cancer	0.000107	0.00292	CcSEcCtD
Pimecrolimus—Body temperature increased—Capecitabine—esophageal cancer	0.000107	0.00292	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—esophageal cancer	0.000105	0.00287	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000104	0.00285	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methotrexate—esophageal cancer	0.000101	0.00275	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—esophageal cancer	0.0001	0.00273	CcSEcCtD
Pimecrolimus—Hypersensitivity—Capecitabine—esophageal cancer	9.96e-05	0.00272	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methotrexate—esophageal cancer	9.87e-05	0.0027	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—esophageal cancer	9.78e-05	0.00267	CcSEcCtD
Pimecrolimus—Pruritus—Capecitabine—esophageal cancer	9.57e-05	0.00261	CcSEcCtD
Pimecrolimus—Diarrhoea—Capecitabine—esophageal cancer	9.25e-05	0.00253	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.17e-05	0.0025	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—esophageal cancer	9.04e-05	0.00247	CcSEcCtD
Pimecrolimus—Dyspnoea—Methotrexate—esophageal cancer	8.97e-05	0.00245	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.69e-05	0.00237	CcSEcCtD
Pimecrolimus—Pain—Methotrexate—esophageal cancer	8.61e-05	0.00235	CcSEcCtD
Pimecrolimus—Vomiting—Capecitabine—esophageal cancer	8.6e-05	0.00235	CcSEcCtD
Pimecrolimus—Rash—Capecitabine—esophageal cancer	8.52e-05	0.00233	CcSEcCtD
Pimecrolimus—Dermatitis—Capecitabine—esophageal cancer	8.52e-05	0.00233	CcSEcCtD
Pimecrolimus—Headache—Capecitabine—esophageal cancer	8.47e-05	0.00231	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—esophageal cancer	8.23e-05	0.00225	CcSEcCtD
Pimecrolimus—Nausea—Capecitabine—esophageal cancer	8.03e-05	0.00219	CcSEcCtD
Pimecrolimus—Urticaria—Methotrexate—esophageal cancer	8e-05	0.00218	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—esophageal cancer	7.96e-05	0.00217	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—esophageal cancer	7.96e-05	0.00217	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methotrexate—esophageal cancer	7.42e-05	0.00203	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—esophageal cancer	7.12e-05	0.00194	CcSEcCtD
Pimecrolimus—Diarrhoea—Methotrexate—esophageal cancer	6.89e-05	0.00188	CcSEcCtD
Pimecrolimus—Vomiting—Methotrexate—esophageal cancer	6.4e-05	0.00175	CcSEcCtD
Pimecrolimus—Rash—Methotrexate—esophageal cancer	6.35e-05	0.00173	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—esophageal cancer	6.34e-05	0.00173	CcSEcCtD
Pimecrolimus—Headache—Methotrexate—esophageal cancer	6.3e-05	0.00172	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—CALR—esophageal cancer	6.01e-05	0.000697	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1A—esophageal cancer	6e-05	0.000697	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KMT2D—esophageal cancer	5.99e-05	0.000696	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CSNK1A1—esophageal cancer	5.99e-05	0.000695	CbGpPWpGaD
Pimecrolimus—Nausea—Methotrexate—esophageal cancer	5.98e-05	0.00163	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—esophageal cancer	5.94e-05	0.000689	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—esophageal cancer	5.92e-05	0.000688	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FBXW7—esophageal cancer	5.83e-05	0.000678	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CREBBP—esophageal cancer	5.81e-05	0.000675	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FBXW7—esophageal cancer	5.81e-05	0.000675	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HMGB1—esophageal cancer	5.81e-05	0.000674	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—RB1—esophageal cancer	5.79e-05	0.000672	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—CDKN1A—esophageal cancer	5.73e-05	0.000665	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1A—esophageal cancer	5.73e-05	0.000665	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—CDKN1A—esophageal cancer	5.73e-05	0.000665	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—PIK3CA—esophageal cancer	5.69e-05	0.000661	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—CDKN1A—esophageal cancer	5.68e-05	0.000659	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—PIK3CA—esophageal cancer	5.65e-05	0.000656	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HIST1H2BM—esophageal cancer	5.65e-05	0.000656	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—CDKN1A—esophageal cancer	5.63e-05	0.000653	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—CDKN1A—esophageal cancer	5.6e-05	0.00065	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDE4D—esophageal cancer	5.6e-05	0.00065	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—EGFR—esophageal cancer	5.57e-05	0.000647	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ELMO1—esophageal cancer	5.45e-05	0.000633	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—esophageal cancer	5.39e-05	0.000626	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADCYAP1—esophageal cancer	5.34e-05	0.00062	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—esophageal cancer	5.33e-05	0.000619	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GNG7—esophageal cancer	5.33e-05	0.000618	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—CDKN1A—esophageal cancer	5.3e-05	0.000615	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	5.27e-05	0.000612	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—EGFR—esophageal cancer	5.25e-05	0.000609	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	5.21e-05	0.000605	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—esophageal cancer	5.09e-05	0.000591	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—esophageal cancer	5.07e-05	0.000589	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ELMO1—esophageal cancer	5.03e-05	0.000584	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—EGFR—esophageal cancer	5.01e-05	0.000582	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—XIAP—esophageal cancer	4.99e-05	0.00058	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—EGFR—esophageal cancer	4.99e-05	0.000579	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—esophageal cancer	4.99e-05	0.000579	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—EGFR—esophageal cancer	4.96e-05	0.000576	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	4.95e-05	0.000575	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—EGFR—esophageal cancer	4.94e-05	0.000573	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TPI1—esophageal cancer	4.92e-05	0.000571	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GSTO1—esophageal cancer	4.92e-05	0.000571	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CFL1—esophageal cancer	4.91e-05	0.000571	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	4.89e-05	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—WWOX—esophageal cancer	4.89e-05	0.000567	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—esophageal cancer	4.87e-05	0.000565	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—PIK3CA—esophageal cancer	4.84e-05	0.000561	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ABL1—esophageal cancer	4.8e-05	0.000558	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNA1—esophageal cancer	4.72e-05	0.000548	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ALDOB—esophageal cancer	4.71e-05	0.000547	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—LGALS3—esophageal cancer	4.71e-05	0.000547	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFBR2—esophageal cancer	4.7e-05	0.000546	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL2—esophageal cancer	4.69e-05	0.000545	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FKBP1A—esophageal cancer	4.65e-05	0.00054	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—EGFR—esophageal cancer	4.64e-05	0.000539	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—esophageal cancer	4.64e-05	0.000539	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—EGFR—esophageal cancer	4.64e-05	0.000539	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	4.64e-05	0.000539	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—esophageal cancer	4.63e-05	0.000537	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—EGFR—esophageal cancer	4.6e-05	0.000535	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—ERBB2—esophageal cancer	4.56e-05	0.00053	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—esophageal cancer	4.56e-05	0.00053	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—PIK3CA—esophageal cancer	4.55e-05	0.000529	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—WIF1—esophageal cancer	4.54e-05	0.000528	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—EGFR—esophageal cancer	4.54e-05	0.000527	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GAPDH—esophageal cancer	4.54e-05	0.000527	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIST1H2BM—esophageal cancer	4.54e-05	0.000527	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SMAD4—esophageal cancer	4.45e-05	0.000516	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—esophageal cancer	4.43e-05	0.000514	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PSME1—esophageal cancer	4.38e-05	0.000509	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PSME2—esophageal cancer	4.38e-05	0.000509	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—PIK3CA—esophageal cancer	4.37e-05	0.000507	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ANXA1—esophageal cancer	4.36e-05	0.000507	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—PIK3CA—esophageal cancer	4.35e-05	0.000505	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—PIK3CA—esophageal cancer	4.33e-05	0.000502	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—PIK3CA—esophageal cancer	4.31e-05	0.0005	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—EGFR—esophageal cancer	4.3e-05	0.000499	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—PIK3CA—esophageal cancer	4.28e-05	0.000498	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SST—esophageal cancer	4.24e-05	0.000493	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—esophageal cancer	4.22e-05	0.00049	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CSNK1A1—esophageal cancer	4.19e-05	0.000487	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ACTB—esophageal cancer	4.18e-05	0.000485	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN1A—esophageal cancer	4.16e-05	0.000483	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH3—esophageal cancer	4.14e-05	0.00048	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GHRL—esophageal cancer	4.14e-05	0.00048	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—esophageal cancer	4.11e-05	0.000478	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTPN2—esophageal cancer	4.08e-05	0.000474	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FBXW7—esophageal cancer	4.07e-05	0.000472	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—B2M—esophageal cancer	4.04e-05	0.000469	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—esophageal cancer	4.03e-05	0.000468	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PIK3CA—esophageal cancer	4.03e-05	0.000468	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PIK3CA—esophageal cancer	4.03e-05	0.000468	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—XIAP—esophageal cancer	4.01e-05	0.000465	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PIK3CA—esophageal cancer	4e-05	0.000464	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—esophageal cancer	3.96e-05	0.00046	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—EP300—esophageal cancer	3.96e-05	0.00046	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	3.95e-05	0.000458	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PIK3CA—esophageal cancer	3.94e-05	0.000458	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PFN1—esophageal cancer	3.92e-05	0.000455	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—CDKN1A—esophageal cancer	3.9e-05	0.000453	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	3.89e-05	0.000452	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PSME2—esophageal cancer	3.81e-05	0.000443	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PSME1—esophageal cancer	3.81e-05	0.000443	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HSPA5—esophageal cancer	3.78e-05	0.000439	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PIK3CA—esophageal cancer	3.73e-05	0.000433	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—B2M—esophageal cancer	3.73e-05	0.000433	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	3.71e-05	0.000431	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH2—esophageal cancer	3.71e-05	0.000431	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CALR—esophageal cancer	3.66e-05	0.000425	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	3.66e-05	0.000425	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR4—esophageal cancer	3.64e-05	0.000423	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HIF1A—esophageal cancer	3.64e-05	0.000423	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ENO1—esophageal cancer	3.57e-05	0.000415	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	3.57e-05	0.000415	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FBXW7—esophageal cancer	3.54e-05	0.000411	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ELMO1—esophageal cancer	3.52e-05	0.000409	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PSME2—esophageal cancer	3.52e-05	0.000409	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PSME1—esophageal cancer	3.52e-05	0.000409	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKAP13—esophageal cancer	3.44e-05	0.0004	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HMGB1—esophageal cancer	3.38e-05	0.000393	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CALR—esophageal cancer	3.38e-05	0.000392	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS2—esophageal cancer	3.31e-05	0.000384	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFBR2—esophageal cancer	3.29e-05	0.000382	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOTCH1—esophageal cancer	3.28e-05	0.000381	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FBXW7—esophageal cancer	3.27e-05	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIST1H2BM—esophageal cancer	3.18e-05	0.000369	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—esophageal cancer	3.16e-05	0.000367	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDE4D—esophageal cancer	3.15e-05	0.000366	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CASP8—esophageal cancer	3.12e-05	0.000363	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMAD4—esophageal cancer	3.11e-05	0.000362	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CREBBP—esophageal cancer	3.11e-05	0.000361	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNG7—esophageal cancer	3e-05	0.000348	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CREBBP—esophageal cancer	2.97e-05	0.000345	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—esophageal cancer	2.83e-05	0.000329	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—XIAP—esophageal cancer	2.81e-05	0.000326	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ABL1—esophageal cancer	2.8e-05	0.000325	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PIK3CA—esophageal cancer	2.75e-05	0.000319	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2—esophageal cancer	2.68e-05	0.000311	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS3—esophageal cancer	2.66e-05	0.000309	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNA1—esophageal cancer	2.65e-05	0.000308	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFBR2—esophageal cancer	2.64e-05	0.000307	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL2—esophageal cancer	2.64e-05	0.000306	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—esophageal cancer	2.6e-05	0.000302	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HIF1A—esophageal cancer	2.55e-05	0.000296	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SMAD4—esophageal cancer	2.5e-05	0.00029	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—esophageal cancer	2.5e-05	0.00029	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—esophageal cancer	2.49e-05	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PSME1—esophageal cancer	2.47e-05	0.000286	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PSME2—esophageal cancer	2.47e-05	0.000286	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ANXA1—esophageal cancer	2.45e-05	0.000285	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KDR—esophageal cancer	2.44e-05	0.000283	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—esophageal cancer	2.43e-05	0.000283	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SST—esophageal cancer	2.39e-05	0.000277	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH3—esophageal cancer	2.33e-05	0.00027	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GHRL—esophageal cancer	2.33e-05	0.00027	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH1—esophageal cancer	2.3e-05	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FBXW7—esophageal cancer	2.29e-05	0.000266	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1A—esophageal cancer	2.23e-05	0.000258	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1A—esophageal cancer	2.14e-05	0.000248	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1A—esophageal cancer	2.13e-05	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—esophageal cancer	2.12e-05	0.000246	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EP300—esophageal cancer	2.12e-05	0.000246	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH2—esophageal cancer	2.09e-05	0.000242	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CREBBP—esophageal cancer	2.08e-05	0.000242	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIF1A—esophageal cancer	2.05e-05	0.000238	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EP300—esophageal cancer	2.02e-05	0.000235	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.99e-05	0.000231	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.99e-05	0.000231	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—esophageal cancer	1.86e-05	0.000216	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—esophageal cancer	1.86e-05	0.000216	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFBR2—esophageal cancer	1.85e-05	0.000215	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOTCH1—esophageal cancer	1.84e-05	0.000214	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—esophageal cancer	1.82e-05	0.000211	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CREBBP—esophageal cancer	1.81e-05	0.00021	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—esophageal cancer	1.8e-05	0.00021	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—esophageal cancer	1.76e-05	0.000205	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMAD4—esophageal cancer	1.75e-05	0.000203	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—esophageal cancer	1.74e-05	0.000202	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—esophageal cancer	1.73e-05	0.000201	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—esophageal cancer	1.73e-05	0.0002	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA1—esophageal cancer	1.69e-05	0.000197	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.69e-05	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CREBBP—esophageal cancer	1.67e-05	0.000194	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—esophageal cancer	1.57e-05	0.000182	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—esophageal cancer	1.56e-05	0.000181	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA2—esophageal cancer	1.55e-05	0.00018	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—esophageal cancer	1.54e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—esophageal cancer	1.52e-05	0.000176	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—esophageal cancer	1.5e-05	0.000175	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—esophageal cancer	1.5e-05	0.000174	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—esophageal cancer	1.5e-05	0.000174	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1A—esophageal cancer	1.49e-05	0.000173	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.44e-05	0.000167	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADH7—esophageal cancer	1.44e-05	0.000167	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—esophageal cancer	1.43e-05	0.000166	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EP300—esophageal cancer	1.42e-05	0.000165	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—esophageal cancer	1.4e-05	0.000163	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—esophageal cancer	1.37e-05	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—esophageal cancer	1.37e-05	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1A—esophageal cancer	1.3e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH1—esophageal cancer	1.29e-05	0.00015	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.26e-05	0.000147	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—esophageal cancer	1.24e-05	0.000143	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EP300—esophageal cancer	1.23e-05	0.000143	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—esophageal cancer	1.21e-05	0.00014	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMP—esophageal cancer	1.21e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1A—esophageal cancer	1.2e-05	0.000139	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.17e-05	0.000136	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CREBBP—esophageal cancer	1.17e-05	0.000136	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.14e-05	0.000133	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EP300—esophageal cancer	1.14e-05	0.000132	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.09e-05	0.000127	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TPI1—esophageal cancer	1.09e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—esophageal cancer	1.05e-05	0.000122	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—esophageal cancer	1.05e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.05e-05	0.000122	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—esophageal cancer	1.01e-05	0.000118	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.01e-05	0.000117	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CRABP1—esophageal cancer	9.99e-06	0.000116	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—esophageal cancer	9.92e-06	0.000115	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—esophageal cancer	9.8e-06	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—esophageal cancer	9.7e-06	0.000113	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNG7—esophageal cancer	9.5e-06	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—esophageal cancer	9.12e-06	0.000106	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.9e-06	0.000103	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—esophageal cancer	8.66e-06	0.000101	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.47e-06	9.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—esophageal cancer	8.42e-06	9.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1A—esophageal cancer	8.38e-06	9.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.37e-06	9.72e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EP300—esophageal cancer	7.97e-06	9.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO1—esophageal cancer	7.94e-06	9.21e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS1—esophageal cancer	7.94e-06	9.21e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PSME2—esophageal cancer	7.82e-06	9.08e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PSME1—esophageal cancer	7.82e-06	9.08e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—esophageal cancer	6.95e-06	8.07e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—esophageal cancer	6.8e-06	7.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.75e-06	7.84e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.34e-06	7.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—esophageal cancer	5.9e-06	6.85e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.79e-06	6.72e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—esophageal cancer	5.71e-06	6.63e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.56e-06	6.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.71e-06	4.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—esophageal cancer	3.33e-06	3.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.04e-06	3.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EP300—esophageal cancer	2.53e-06	2.94e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.87e-06	2.17e-05	CbGpPWpGaD
